知镜 Cognispect · 医学文献与研究工作台

FDA Approval Summary: Tarlatamab for the Treatment of Extensive-Stage Small Cell Lung Cancer.

Liu Y, Nashed J, Barone AK, Yuan M, Amatya AK, Xiang Y, Zhao H, Bi Y, Pegues MA, Miller CP, Lane AR, Mixter BD, Tang S, Pazdur R, de Claro RA, Larkins E.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026-04-01 · PMID 41587109

文献摘要

On May 16, 2024, the FDA granted accelerated approval to tarlatamab-dlle (hereafter referred to as tarlatamab) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. The approval was based on data from DeLLphi-301 (NCT05060016), an open-label, multicenter, multicohort trial involving patients with relapsed/refractory SCLC with disease progression after platinum-based chemotherapy and at least one other line of systemic therapy. Among 99 patients, the overall response rate (ORR) was 40% [95% confidence interval (CI), 31%-51%], with a median duration of response (DoR) of 9.7 months (range, 2.7-20.7+ months). The most common adverse reactions (≥20%) were cytokine release syndrome (CRS), fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, constipation, anemia, and nausea. Product labeling includes a Boxed Warning for serious or life-threatening CRS and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS).

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。